# An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.

> **NCT01480271** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 61 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** 2 ng GSK2445053
- **DRUG:** 20ng GSK2445053
- **DRUG:** 100ng GSK2445053
- **DRUG:** 200ng GSK2445053
- **DRUG:** 400ng GSK2445053
- **DRUG:** 1000ng GSK2445053
- **DRUG:** 2000ng GSK2445053
- **DRUG:** 4000ng GSK2445053
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01480271
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-30
- **Primary completion:** 2011-09-30
- **Final completion:** 2011-09-30
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480271, "An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01480271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*